Amphastar Pharma (AMPH) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2019
November 7, 2019 4:06 PM ESTReports Net Revenues of $80.1 Million for the Three Months Ended September 30, 2019
RANCHO CUCAMONGA, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (Amphastar or the Company) today reported results for the three months ended September 30, 2019.
Third Quarter Highlights
Net revenues of $80.1 million for the third quarterGAAP net income of $1.3 million, or $0.03 per share, for the third quarterAdjusted non-GAAP net income of $5.2 million, or $0.10 per share, for the third quarterDr. Jack Zhang, Amphastars Chief Executive Officer, commented: A significant accomplishment... More
